COMP <GO>
CPIX vs ABBV // NET PROFIT MARGIN
Cumberland Pharmaceuticals Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: CPIX 3
— ABBV 7
▲ NET PROFIT MARGIN LEADER: ABBV
LAST: $4.69 (+7.82%) • MKT CAP: $65.2M
net-margins
-6.40%
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
net-margins
6.90%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CPIX VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CPIX | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 85.00% | 70.20% | +14.80 | CPIX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -16.40% | 29.00% | -45.40 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 7.42% | 3.47% | +3.95 | CPIX | /fcf-yield <GO> |
| Operating Margin | -6.30% | 24.60% | -30.90 | ABBV | /operating-margins <GO> |
| Net Profit Margin ACTIVE | -6.40% | 6.90% | -13.30 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 17.60% | 8.60% | +9.00 | CPIX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.72 | 5.33 | -4.61 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 35.3 | 65.1 | -29.85 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $65.2M | $513.86B | -$513.79B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CPIX REV | ABBV REV | CPIX GROSS % | ABBV GROSS % | CPIX FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $44.5M | $61.16B | 85.0% | 70.2% | $4.8M | $17.82B |
| FY 2024 | $37.9M | $56.33B | 82.6% | 70.0% | -$678.6K | $17.83B |
| FY 2023 | $39.6M | $54.32B | — | — | $6.1M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CPIX // BETA —
ABBV // BETA 1.15